InDevR's new VaxArray to improve potency testing for measles and rubella vaccines

InDevR announced today that it will be pursued by VaxArray potency badays for measles (M) and rubella vaccines sponsored by the Bill & Melinda Gates Foundation. The long-term objective is to create in vitro measles and rubella potency badays in order to deliver high quality MR vaccines to market faster and to lower production costs. The VaxArray platform, which was first developed and validated for more efficient potency testing of influenza vaccines. Accurate measurement of vaccine "potency" is critical because it allows vaccine manufacturers to package the right amount of active ingredient. Under-filling can result in a sub-potent vaccine that does not protect the patient and over-filling can cause a safety issue – both cases result in a

Measles and rubella ("German Measles") are highly contagious diseases that have significant health impact around the world. According to the Measles and Rubella Initiative, before the year 2000 over a half million children died each year from measles and badociated complications. This disease can be prevented by well-proven vaccines. In order to deliver the vaccine to the world, it would be beneficial to streamline the vaccine manufacturing process

Dr. Klaus Stohr, Head of Global Public Policy at Novartis Vaccines, commented "There is no doubt that measles and rubella vaccines will remain the cornerstones of pediatric immunization programs in both developed and developing countries. to increase the availability of these life-saving vaccines worldwide. "

Currently, time-consuming biological tests such as tissue culture infectivity dose (TCID50), which takes 1-2 weeks to complete, are used to measure potency for MR vaccinated. The VaxArray platform offers 2-hour badays for tracking potency throughout the vaccine manufacturing process, which could reduce production time by weeks and possibly get the vaccine to market. For example, measles and rubella, TCID50, are currently 3000 and 1000 infectious particles / dose, respectively. A more accurate potency baday for each of these live attenuated antigens viruses would reduce the risk of rejection.

InDevR's CEO, Kathy Rowlen, Ph.D., said, "We are thrilled to partner with the Bill & Melinda Gates Foundation. Their sponsorship of this project is further validation of the potential of VaxArray platform for enhancing vaccine potency testing. "